Form 4: ATAI Life Sciences CFO Anne Nagengast Johnson Reports Stock Transaction

Anne Nagengast Johnson, CFO of ATAI Life Sciences N.V., reports the vesting and conversion of restricted stock units into 100,000 common shares on March 14, 2025.

Summary

• On March 19, 2025, a Form 4 filing was submitted to the SEC by Ryan Barrett, Attorney-in-fact, on behalf of Anne Nagengast Johnson, the Chief Financial Officer of ATAI Life Sciences N.V.
• The filing reports a transaction that occurred on March 14, 2025, where 100,000 restricted stock units were converted into 100,000 common shares.
• These restricted stock units vested in two tranches: 50% on March 14, 2024, and the remaining 50% on March 14, 2025.
• Following the transaction, Johnson directly owns 173,590 common shares.

Sentiment

Score: 5

Explanation: This is a neutral report of a standard transaction related to executive compensation. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, and is a normal part of corporate governance.

Stakeholder Impact

• The transaction has a minor dilutive effect on existing shareholders due to the issuance of new common shares.

Key Dates

Keywords

ATAI Life Sciences, Form 4, SEC Filing, Insider Trading, Stock Transaction, Restricted Stock Units, Common Shares, CFO, Anne Nagengast Johnson